Implications of Inflation Reduction Act negotiation - the known unknowns

The Inflation Reduction Act could be the most significant development in the US pharma and biotech market since the creation of Medicare Part D. We’re here to help you understand the impact on your brands.

In our previous articles, we discussed the impact of the Inflation Reduction Act on US healthcare and how to prepare for the Medicare Drug Price negotiation process. In this article, we address several key questions which arise from the CMS’ initial guidance and try to bring some known to the unknowns.

The Inflation Reduction Act sets a ceiling price for the maximum fair price (MFP) based on the length of time a therapy has been on the market. But what will be CMS’…